<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="HA87FF7CB07104D6B81894FCCA0BEE8B4" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 7640 IH: To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-05-03</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 7640</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220503">May 3, 2022</action-date><action-desc><sponsor name-id="B001257">Mr. Bilirakis</sponsor> (for himself and <cosponsor name-id="B001251">Mr. Butterfield</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as <quote>orphan drugs</quote>).</official-title></form><legis-body id="H97D817B7061641B6B5EE98C478E57C23" style="OLC"><section id="H17A168625F0F449EA5E6A28013EEBA22" section-type="section-one"><enum>1.</enum><header>Reauthorization of grants and contracts for development of orphan drugs</header><text display-inline="no-display-inline">Section 5(c) of the Orphan Drug Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ee">21 U.S.C. 360ee(c)</external-xref>) is amended by striking <quote>2018 through 2022</quote> and inserting <quote>2023 through 2027</quote>. </text></section></legis-body></bill> 

